Cervical carcinogenesis, the second leading cause of cancer death in women worldwide, is caused by multiple types of human papillomaviruses (HPVs). To investigate a possible role for HPV in a cervical carcinoma that was HPV-negative by PCR testing, we performed HPV DNA hybridization capture plus massively parallel sequencing. This detected a subgenomic, URR-E6-E7-E1 segment of HPV70 DNA, a type not generally associated with cervical cancer, 
Introduction
Infections with HPV types that are classified as high-risk by epidemiological criteria (hrHPVs) underlie the vast majority of invasive cervical carcinomas (ICCs) (1) . ICCs are responsible for 4.5% of cancer deaths in women worldwide and comprise a substantial fraction of the estimated 12% of cancers worldwide caused by various viruses (2) . Multiple large studies showed hrHPV types to be present in at least 90% of ICC's using established, PCR-or hybridization-based methods for viral DNA detection (3, 4) . HPV types categorized as Group 1 known carcinogens by the International Agency for Research on Cancer (IARC) working group are phylogenetically classified within the high-risk Alphapapillomavirus-7 and Alphapapillomavirus-9 clades of the Alphapapillomavirus genus and include the HPV types HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, and HPV59, with HPV16 and HPV18 being the most frequently detected types in ICC (5) . Despite also belonging to the species Alphapapillomavirus 7 and Alphapapillomavirus 9, other less frequent HPV types also belonging to these clades (HPV26, HPV30, HPV34, HPV53, HPV66, HPV67, HPV69, HPV70, HPV73, HPV82 and HPV85), do not fulfill the rigorous epidemiological criteria required to be categorized as Group 1 carcinogens (5). At least 40 HPV types are known to infect the urogenital tract (1, 6, 7) . Up to ~10% of invasive cervical cancers are currently considered HPV-negative (3, 4) . This might be because of tissue sampling errors, the portion of the HPV genome targeted by the assay was deleted, or the tumor is associated with a low prevalence HPV type (8) . An additional formal possibility is that some small fraction has a non-HPV etiology.
Population screening for women for cervical cancer historically has been accomplished by cytology (Papanicolaou test), but multiple clinical trials have provided evidence of improved sensitivity of hrHPV testing for detection of cervical cancer precursor lesions compared to cytology alone over multiple rounds of screening and follow up (9) (10) (11) (12) (13) . The HPV types included in the screening assays are based on epidemiological prevalence data that balance sensitivity and specificity so as not to over-triage women to secondary screening such as colposcopy, and they currently include at most the 14 hrHPV types. Exclusion of less prevalent types from HPV screening reduces possible iatrogenic morbidity from subsequent colposcopy and excisional procedures following detection of viral types of uncertain pathological significance, and also reduces the costs involved in more extensive testing (14) . Unlike population based screening, diagnostic HPV testing of identified pre-invasive and invasive cervical lesions is applicable to research driven assays.
While at least half of sexually active women incur a genital tract HPV infection during their lifetime (15) , cervical tumorigenesis occurs in only a very small fraction of infected women.
Tumorigenesis proceeds in a small fraction of women through a series of histopathologically defined, cervical intraepithelial neoplasia (CIN) lesions of progressively decreasing likelihood, CIN1, CIN2, and CIN3. The vast majority of HPV infections resolve spontaneously, with even most CIN lesions resolving spontaneously and only 20% to 30% of CIN3 lesions progressing to life-threatening ICC.
HPV infection proceeds with the ~8 kbp viral DNA genome replicating as a circular episome initially in the basal epithelial cell layer. A key step in HPV-associated tumorigenesis is integration of viral DNA into the human genome (16) (17) (18) (19) . At least part of the viral genome is inserted into human DNA in most HPV-induced ICC's, and the integration process is thought to be mediated by host DNA repair mechanisms. Integration causes stable association of the virally-encoded oncogenes with a host cell, triggers human genome rearrangements, and drives expression of the human oncogenes that flank the sites of integration (20) (21) (22) (23) (24) (25) . In most ICC's, the HPV genome is inserted near one allele of a human, dominant-acting oncogene, and many human oncogenes have been identified as recurring HPV insertion sites in tumors (22, (26) (27) (28) (29) (30) .
The presence of viral DNA adjacent to such human oncogenes is thought to be a consequence of integration occurring at a stochastic position within the human genome, followed by selectively advantageous, clonal proliferation of cells that suffered an integration near such oncogenes. Insertional oncogenesis by activation of flanking oncogenes is a long studied and thoroughly established mechanism of tumorigenesis by various retroviruses in experimental and naturally occurring animal systems in which insertion of viral DNA containing strong transcriptional elements, particularly enhancers, alters the transcription of the flanking gene (31) (32) (33) (34) (35) . This is also the causal mechanism in the tumors that occurred during gene therapy studies in humans (36, 37) . HPV activation of nearby oncogene transcription may entail a variety of mechanisms including fusion transcripts. These initiate at viral promoters and proceed into the host genes. Viral enhancers may also activate flanking oncogene promoters (38) (39) (40) .
Approaches to detect integrated viral DNA have included RNA sequencing (RNAseq) to detect fusion transcripts, and DNA sequencing strategies including PCR or hybridization capture to identify the junctions between inserted HPV and human genome DNA (20) (21) (22) (23) . However, in most instances only one of the two junctions between the linear HPV DNA fragment and human DNA was identified, and structural characterization of the inserted viral DNA was incomplete or inferred. Here we describe the use of a multiple HPV type, hybridization capture approach yielding sufficient DNA recovery and massively parallel sequencing depth to identify both junctions of an inserted HPV DNA. Combined with additional molecular genetic techniques, this allows comprehensive, robust characterization of HPV cervical tumorigenesis.
Results
HPV DNA analysis was applied to a cervical carcinoma chosen specifically based on its HPV-negative, clinical testing status at the time of cancer diagnosis. A 46-year-old woman presented at the emergency room of our institution with International Federation of Gynecology and Obstetrics (FIGO) stage IIB, squamous cell ICC. HPV testing using the cobas test (Roche Molecular Systems), which detects 14 hrHPV types by PCR of a viral L1 gene segment followed by probe hybridization, was negative. Tumor DNA was subjected to hybridization capture enrichment of HPV DNA followed by massively parallel, next generation, DNA sequencing (HC+NGS) to search for any HPV DNA present in the lesion and, if so, determine whether it was inserted into the human genome. Targeted enrichment was accomplished using   hybridization to a custom designed capture probe set containing DNA from 15 different hrHPV   types (HPV 6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV52,   HPV56, HPV58, HPV59, HPV68, Figure 1) . While HPV70 was not specifically targeted by the probes used, the HPV70 DNA fragments were presumably recovered by hybridization to related species Alphapapillomavirus 7 types in the set, most likely HPV39 and HPV68. Forced alignment to a secondary custom genome containing only the HPV types included in the hybridization probe set was attempted, however alignment in this setting was both lower in unique reads (72,681 aligned read pairs to HPV type 68) and identity (<90%).
More importantly, detection of HPV70 DNA demonstrated that this clinically HPV-negative tumor in fact did contain HPV, albeit from an uncommon type currently not classified as high risk.
The HC+NGS analysis detected junctions between the ends of the viral segment and sequences in the last intron of the human BCL11B gene between the third and fourth exons (Figure 2A) . BCL11B encodes a Kruppel-like zinc finger protein that was previously identified as an integration site of HPV16 in at least two ICC's (41, 42) and is mutated in other human cancers, most notably T-lymphocyte tumors (43) (44) (45) (46) (47) . The occurrence of the two junctions at nearby genomic positions in BCL11B suggested that the 3980 bp HPV70 segment comprised a single insertion at this site (Figure 2A) . To confirm the implied structure of HPV70 in a BCL11B allele, the tumor was subjected to intensive molecular genetic characterization by long range DNA sequencing, short range whole genome sequencing (WGS), Affymetrix Genome-Wide Human SNP Array 6.0 analysis, and RNA sequencing (RNAseq).
Long range DNA sequencing utilizing an Oxford Nanopore MinION flowcell yielded 3.56X haploid genome coverage including three reads encompassing the HPV70 DNA insertion in BCL11B (Figure 2B ). This unambiguously confirmed the structure of the insertion. WGS at 60X average genome coverage also confirmed both virus-human junctions, the sequence of the HPV70 segment detected by HC+NGS, and the absence of the remainder of HPV70 ( Figure   2C ). The number of WGS read counts across HPV70 was about one-third the number across BCL11B, indicating that HPV70 DNA was present in one allele of the BCL11B gene, and that one or more normal BCL11B alleles were also present, which is consistent with the insertion allele acting dominantly in tumorigenesis. Human DNA copy number was assessed genomewide by generating a Ginko plot of WGS reads across the human genome ( Figure 2D) . Gain of the entire chromosome 3q arm was detected, along with copy number increases on human chromosomes 1q, 5p, 8, 12q and 14q, the latter including the BCL11B locus. 3q trisomy, which is highly recurrent in ICC, has been proposed to define transition from cervical dysplasia to invasive carcinoma through effects of the telomerase reverse transcriptase encoding TERT gene (48, 49) . The 1q, 5p, 8, 12q and 14q copy number variations were also detected by genome-wide SNP analysis ( Figure 2E ), thus confirming their presence in the tumor. The observation that they were not as pronounced as the 3q trisomy indicated that they were less uniform among the tumor cells and likely involved multiple segments of the cognate chromosomes.
To investigate the extent of variability of the BCL11B copy number among the tumor cells, fluorescent in situ hybridization (FISH) was performed on histological sections of the tumor using a BAC probe encompassing the BCL11B gene ( Figure 2F ). Quantification showed that most cells contained between two and ten BCL11B loci, with modal number three ( Figure 2H ). About 4% of cells had 50 or more copies (Figures 2F, 2H ). These cells were very large compared to the other tumor cells ( Figure 2F ) and were evident in standard, hematoxylin plus eosin stained, histopathology sections ( Figure 2G ). In summary, there was extensive variability in BCL11B copy number among the tumor cells. Transcripts with the most frequently detected splice junction (E1^E4 5'ss to 3'ss exon 4) encoded a fusion protein with the first five amino acids of HPV70 E1 fused to the portion of BCL11B encoding all six of its zinc fingers ( Figure 3F ). The E1^E4 splice to cryptic exon 3B joined the first five HPV70 E1 amino acids in frame to an ORF that completely spanned exon 3B, which in turn was spliced to exon 4 ( Figure 3G) . However, the splice junction from exon 3B to exon 4 caused exon 4 to be read in a different ORF than normal and encompassing 66 amino acids and no zinc fingers ( Figure 3G) . Similarly, while transcripts encompassing the standard BCL11B exons 1, 2, 3, and 4 encoded the standard six Zn-finger protein (Figure 3H) , splicing of BCL11B transcripts from exon 2 to exon 3B fused the ORFs in frame, but the junction from exon 3B to exon 4 caused the same frameshift as in the viral fusion transcripts (Figure 3I) . In summary, the HPV70 DNA insertion resulted mainly in HPV70-BCL11B fusion transcripts encoding an unusual, N-terminally truncated form of the BCL11B oncogene with five HPV70 E1 amino acids at the N-terminus ( Figure 3F ). In addition, less abundant transcripts containing cryptic exon 3B that causes exon 4 of BCL11B to be read in a different ORF were detected with either viral or BCL11B encoded amino acids at the N-termini (Figures 3G and 3I ).
To verify that the HPV70-BCL11B fusion RNAs were present, RT-PCR was performed on tumor RNA using one primer in virus sequences and the other in exon 4 ( Figure 4A ). This confirmed the presence of the fusion transcripts ( Figure 4B ). In addition to RNA from the tumor, a formalin fixed, paraffin embedded tissue fragment was obtained from a histopathology specimen from the same patient archived three years before tumor resection. The patient was diagnosed with CIN3 at that time, but was lost to follow-up. Both RNA and DNA were both prepared from the archived CIN3 sample. RT-PCR detected the presence of the fusion transcripts at both the tumor and the CIN3 stage ( Figure 4B) . Veracities of the RT-PCR products were confirmed by sequencing of excised bands from the tumor RT-PCR. The more prominent, faster migrating band confirmed splicing from HPV70 E1 to BCL11B exon 4 (Supplementary Figure 4) . The faint upper band was also recovered from the tumor RT-PCR and sequenced thus confirming the structure of HPV70 E1 spliced to exon 3B, and exon 3B spliced to exon 4 of BCL11B in the same RNA (Supplementary Figure 4) . Presence of the 3980 bp HPV70 DNA insertion into BCL11B was also confirmed by PCR testing for the HPV70 L1 junction in the CIN3 biopsy as well as in the tumor ( Figure 4C) . Thus, the HPV70 DNA insertion and fusion transcripts were present in the lesion by the time of CIN3 diagnosis as well as in the eventual tumor.
Discussion
Application of the HC+NGS approach to a cervical tumor identified the presence of HPV70 DNA and discerned the precise fraction of the viral genome present in the tumor. It also revealed that the viral DNA was integrated into one allele of BCL11B in the human genome, a gene that has been previously implicated in human tumorigenesis (43) (44) (45) (46) (47) . Additional molecular genetic analyses identified the viral transcripts in the tumor and ascertained that the HPV70 DNA insertion resulted in fusion transcripts between the virus and portions of the BCL11B gene, including a novel cryptic exon. The finding of the viral insertion and the HPV70-BCL11B exon 4 fusion transcript in the CIN3 sample from the same patient indicated that these events had occurred by the intraepithelial precursor stage of disease and persisted during the invasive carcinoma stage. These results strongly imply that the HPV70 insertion and activation of BCL11B fusion ORF transcription were key events during malignant transformation. HPV70 was previously detected in ICCs and oral cancers (51, 52) , and BCL11B was previously identified as a site of HPV16 integration in at least two cervical cancers (41, 42) . Tumorigenesis by insertion of viral DNA near oncogenes is a thoroughly established oncogenic mechanism (31) (32) (33) (34) (35) . The frequent detection of HPV DNA near oncogenes in virally induced human tumors indicates that insertional oncogenesis is a key mechanism in HPV-induced tumors, and that it may act in concert with HPV-encoded oncogenes, perhaps even replacing them in some instances (40) . Detection of HPV70 DNA integrated into BCL11B and transcriptional activation of it, along with HPV E7 transcripts, strongly implicate HPV70 in this tumor.
Hybridization capture plus massively parallel sequencing has been used and proven to be reliable for identifying human genome integration sites of HPV DNA in tumors (20, 21, 24, 53) . As demonstrated here, this approach is best applied by use of capture DNA probes Targeted enrichment of HPV DNA was performed using hybridization capture probes homologous to the full-length genomes of 15 different HPV types (6, 11, 16, 18, 31, 33, 35, 39, 45, 52, 56, 58, 59, 68, 69) that were custom-designed using the Roche Nimblegen SeqCap EZ System (Roche, Basel, Switzerland). Biotinylated oligonucleotide probes specific for each HPV type were designed at ~150 bp intervals encompassing the positive strands of the complete ~8 kb double strand viral genomes to achieve 100% coverage. For library preparation, tumor genomic DNA was mechanically fragmented to 200 bp (Covaris, Woburn, MA), and Illumina adaptors were ligated at each end. Libraries were then hybridized to the custom HPV capture probes for 72 hours using the Roche target enrichment protocol following manufacture instructions and sequenced on one Illumina HiSeq 2500 lane (Illumina, San Diego, CA) using the paired end 150 bp sequencing mode. After sequencing, we aligned adaptor-cleaned, QCpassed, de-duplicated, paired end reads to a custom human (GRCh37/hg19) plus HPV reference genome containing 143 alpha genus HPV types from the Papillomavirus Episteme(72) using Burrows-Wheeler Aligner (BWA) (73) . Junction fragments were computationally identified using a combination of programs; Delly (74) and SplazerS (75), both of which specify a combined read pair discordancy and split read analysis.
Long sequencing reads using the Oxford Nanopore Technologies (ONT) MinION.
Tumor-derived gDNA was purified and concentrated using the genomic DNA Clean and Concentrator-10 (gDCC-10) kit following manufacturer instructions (Zymo Research); concentration was assessed by Qubit and quality was assessed by Nanodrop (Thermo Fisher Scientific). The purified gDNA was then sheared by g-TUBE (Covaris, Woburn, MA) to 10 kb.
Genomic libraries were prepared using the Oxford Nanopore 1D ligation library prep kit SQK-LSK108 following manufacturer instructions. Two independently prepared tumor DNA libraries were loaded onto two R9.4 flow cells and sequenced using a MinION Mk1b device (ONT) using the standard 48-hour scripts. Post-sequencing base calling and FASTQ extraction was performed using Albacore v2.0 (ONT), whereby raw voltage channel data is translated into canonical nucleotides. All libraries and quality filtered pass reads (Q≥7) were used for the subsequent analysis. Library-specific adaptors were trimmed and possible internal adaptors split using Porechop(76) with default parameters for adaptor identification (90% identity), end trimming (75% identity), and internal splitting (85% identity). Sequence reads were aligned to our custom combined reference genome using Ngmlr (77), a structural variant caller that uses a structural variant aware k-mer search to approximate alignments followed by a banded SmithWaterman final alignment, along with a convex gap cost model to account for higher sequencing error frequencies associated with long reads. Structural variants were called using Sniffles (77) with parameter adjustment for expected low coverage.
Detection of chromosome structural alterations, aneuploidy and copy number variation by whole genome sequencing and SNP analysis.
For whole genome sequencing (WGS), 1 µg of genomic DNA from the tumor was used as input for library preparation using the NEBNext DNA Library Prep Kit (New England Biolabs). DNA was mechanically fragmented to 350 bp (Covaris, Woburn, MA) and the DNA fragments were end-polished, A-tailed, adaptor ligated, PCR amplified by P5 and indexed P7 oligos, and purified (AMPure XP system). The libraries were purified with AMPure XP (Beckman Coulter). QC passed libraries were sequenced on 2 Illumina HiSeq 2500 lanes to achieve 60X genome coverage on the paired end 150 bp mode. Reads with adaptor contamination or low quality (Phred Q30 <80%) were removed. After sequencing, paired end reads were aligned to our custom human (GRCh37/hg19) plus HPV70 reference genome using Burrows-Wheeler Aligner (BWA) (73) . Files were mapped in BAM format, sorted using SAMtools(78), and duplicates removed using Picard (79). Genomic variant detection was accomplished for single nucleotide polymorphisms (SNPs)/small insertions and deletions (indels) using GATK v3.8 (80), structural variant (SV) detection using Delly v0.7.3 (74) , and copy number variants (CNV) detection using control-FREEC (81) . Following genomic variant detection, variants were annotated using the software ANNOVAR (82) . Tumor genomic copy number was also assessed using the Genome-Wide Human SNP array 6.0 (Thermo Fisher Scientific). DNA prehandling and array hybridization were performed according to the manufacturer's instructions (Affymetrix, Santa Clara, CA) and scanned in an Affymetrix GeneChip Scanner 3000. Data analysis and visualization was performed in Chromosomal Analysis Suite v4.0 (ChAS, Thermo Fisher Scientific) with a threshold of minimum 100 kb and 50 markers using NCBI build GRCh37/hg19.
Global transcriptomic profiling of tumor RNA.
Total RNA (2 µg) isolated from six, 10 µm, tumor sections with an RNA integrity number of 9.3 (Agilent 1000) and subjected to oligoT magnetic bead enrichment. Libraries were prepared following the NEB standard protocol as follows: cDNA was synthesized using random hexamer primers and M-MuLV RT (RNaseH-) followed by second strand synthesis with DNA polymerase I and RNaseH. The double stranded cDNA was purified using AMPure XP beads (Beckman Coulter), end tail repaired, adaptor ligated, size-selected, and PCR amplified before Illumina sequencing. 150 bp insert cDNA libraries were sequenced to a depth of 60 million reads on one Illumina HiSeq 2500 lane (Illumina, Inc., San Diego, CA) using the paired end 150 bp mode. Raw image data were transformed to sequenced reads by CASAVA and stored in FASTQ format. Raw reads were then filtered to remove adaptors, reads containing N>10% (N representing undetermined bases), and reads of Qscore (Quality value) of >50% of bases < 5.
Of approximately 144 million reads, 97.8% passed filtering with >96% having Phred scores >30.
Gene model annotation files were downloaded from the genome website browser (NCBI/UCSC/Ensembl) for (GRCh37/hg19) and in custom format from Papillomavirus Episteme (72) for HPV70. Indexes of the custom reference genome were built, and paired-end clean reads were aligned to the reference using STAR v2.5 (83) . HTSeq v0.6.1 (84) was used to count the read numbers mapped of each gene. As there was no tumor-free matched control for this patient, differential expression analysis was not performed. As our main interest was in potential fusion transcripts between BCL11B and HPV70, STAR-Fusion 0.8.0 (85) was used for the detection of fusion transcripts.
Validation of HPV DNA integration junctions & HPV70-BCL11B Fusion Transcripts
To detect the integrated HPV70 DNA segment, PCR primers were designed to flank each side of the HPV70 genome -human genome junctions obtained from HC+NGS split reads. The Institute. 8 µm sections were cut from the diagnostic FFPE tumor block from the patient, and mounted on positively charged slides. Slides were incubated overnight at 56°C prior to FISH hybridization that was performed as previously described (86) . Briefly, the slides were deparaffinized in Hemo-De at room temperature for 10 minutes x 2, dehydrated in 100% ethanol for 5 minutes x 2 and placed on a 50°C slide warmer for 5 minutes. The slides were then pretreated for 24 minutes using the Vysis Paraffin Pretreatment Reagent Kit (Abbott Molecular), and fixed in 10% buffered formalin as per the protocol. The FISH probe was labeled by nick translation using DY-415-aadUTP (Dyomics, Jena, GE, USA) as previously described (86) Figure 4C highlighting the HPV70 (blue), BCL11B exon 3B (gray), and BCL11B exon 4 (green) sequences of the PCR products generated from tumor RNA.
